News
Aytu BioPharma to Participate in September 2022 Investor Conferences
ENGLEWOOD, CO / August 24, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced that Aytu's management team will...
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
First Issued U.S. Patent Covers Methods of Treating a Broad Range of Inherited Aortic Aneurism and Related Conditions Including Vascular Ehlers-Danlos SyndromeMultiple Patent Families Filed in Key Global MarketsENGLEWOOD, CO / August 16, 2022 / Aytu BioPharma, Inc....
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering
ENGLEWOOD, CO / August 15, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of its previously announced underwritten public offering...
Aytu BioPharma Announces Pricing of Public Offering
ENGLEWOOD, CO / August 9, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering of (i) 21,505,814...
Aytu BioPharma Announces Launch of Public Offering
ENGLEWOOD, CO / August 8, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten public offering of shares of its common...
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
ENGLEWOOD, CO / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Chief Executive Officer Josh Disbrow and Chief Financial Officer Mark Oki...
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
ENGLEWOOD, CO / July 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the initiation of the global Phase 3 PREVEnt (Prevention of Ruptures with Enzastaurin for...
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company’s Board of Directors
ENGLEWOOD, CO / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of Vivian Liu to the company's board of directors, effective July 1, 2022. Ms....
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference
ENGLEWOOD, CO / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company will be participating in the Lytham Partners Summer 2022 Investor Conference...
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company HistoryStrategic Priorities Focused on Driving Revenue Growth, Increasing Financial Efficiencies and Performance and Preparing Pipeline for Long-term Value...